"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 5 | 2 | 7 |
| 1996 | 7 | 2 | 9 |
| 1997 | 17 | 2 | 19 |
| 1998 | 18 | 2 | 20 |
| 1999 | 11 | 2 | 13 |
| 2000 | 15 | 6 | 21 |
| 2001 | 10 | 5 | 15 |
| 2002 | 15 | 5 | 20 |
| 2003 | 20 | 5 | 25 |
| 2004 | 15 | 11 | 26 |
| 2005 | 28 | 9 | 37 |
| 2006 | 13 | 17 | 30 |
| 2007 | 17 | 21 | 38 |
| 2008 | 32 | 10 | 42 |
| 2009 | 21 | 20 | 41 |
| 2010 | 32 | 16 | 48 |
| 2011 | 38 | 19 | 57 |
| 2012 | 32 | 17 | 49 |
| 2013 | 37 | 24 | 61 |
| 2014 | 36 | 12 | 48 |
| 2015 | 47 | 28 | 75 |
| 2016 | 56 | 22 | 78 |
| 2017 | 40 | 17 | 57 |
| 2018 | 39 | 21 | 60 |
| 2019 | 35 | 17 | 52 |
| 2020 | 39 | 7 | 46 |
| 2021 | 44 | 14 | 58 |
| 2022 | 17 | 2 | 19 |
| 2023 | 22 | 2 | 24 |
| 2024 | 7 | 14 | 21 |
| 2025 | 9 | 3 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
G-protein coupled receptors in metabolic reprogramming and cancer. Pharmacol Ther. 2025 Jun; 270:108849.
-
Current and emerging treatment perspectives for adults with Waldenstr?m macroglobulinemia. Expert Rev Anticancer Ther. 2025 May; 25(5):485-497.
-
Histone acetylation modulators in breast cancer. Breast Cancer Res. 2025 Mar 31; 27(1):49.
-
MYC-Targeting PROTACs Lead to Bimodal Degradation and N-Terminal Truncation. ACS Chem Biol. 2025 Apr 18; 20(4):896-906.
-
Feasibility and Safety of Intratympanic Administration of Sustained-Exposure Dexamethasone Thermosensitive Gel (OTO-104) for Prevention of Cisplatin-Induced Hearing Loss in Children: A Multisite Phase 2 Randomized Clinical Trial. Pediatr Blood Cancer. 2025 Jun; 72(6):e31680.
-
How I treat acute myeloid leukemia with differentiation therapy. Blood. 2025 Mar 20; 145(12):1251-1259.
-
Cardiovascular Toxicity in Patients Treated for Childhood Cancer: A Scientific Statement From the American Heart Association. Circulation. 2025 Apr 15; 151(15):e926-e943.
-
Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2- metastatic breast cancer: A Flatiron Health database analysis. Breast. 2025 Jun; 81:104448.
-
Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2025 Mar 17; 31(6):965-974.
-
Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation. Blood. 2025 Mar 06; 145(10):1047-1060.